Supplemental Materials: Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS)_JAAD

Name: Supplemental Materials: Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS)_JAAD
Creator: Mendeley Data
Published: 2023-11-08T14:21:17+08:00

DataCite Commons2025-04-01 更新2025-04-16 收录

药物研发

皮肤病学

数据链接：

https://data.mendeley.com/datasets/dkbxwxmtfv 数据链接链接失效反馈

官方服务：

资源简介：

Supplemental information for the manuscript in the Journal of the American Academy of Dermatology (JAAD): "Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS)"

提供机构：

Mendeley Data

创建时间：

2023-11-08